42 results about "Malignant transformation" patented technology

The invention discloses a method for increasing the passage frequency of a mammary epithelial cell line and application of the method, and belongs to the technical field of mammary epithelial cell lines. It is found for the first time that an insulator-stent attachment area exogenous fragment HS4-SAR fragment is connected with a p-Ef1a-SV40LT-Puro vector or a pEF1a-eGFP vector, commercial immortalized cell lines and primary cell lines are transfected, the passage number of mammary gland epithelial cell lines can be remarkably increased, and the mammary gland epithelial cell lines can be obtained. After 120 generations of passage, the cell morphology is still normal, malignant transformation is avoided, and the gene expression level is still not reduced, so that immortalization is realized; the established milk goat mammary gland epithelial cell line still has the capability of synthesizing and secreting protein; the provided method for increasing the passage frequency of the mammary epithelial cell line is simple and easy to operate, has a remarkable effect on an immortalized cell line and a primary cell line, and is expected to increase the passage frequency of stable passage of various mammary epithelial cell lines and reduce the cell cost of related research.

The invention belongs to the technical field of medical biological detection, and particularly relates to a gene marker combination for oral mucosa leukoplakia canceration risk and application of the gene marker combination. The gene marker combination is a combination of TP53, CASP8 and CYP2B6 genes and is obtained by screening through a WES technology, the predicted AUC of the gene marker combination reaches 0.813 (95% CI: 0.710-0.916), and the performance of the gene marker combination is remarkably superior to that of traditional pathological grading. Through Cox risk regression analysis, a high-risk group as an independent factor has significant statistical significance and is superior to traditional indexes such as age and diseased regions. The invention further provides an oral mucosa leukoplakia canceration risk prediction kit and prediction system derived from the gene combination.

The invention provides a mammary nodule malignant transformation risk prediction system and method, a terminal, a medium and a product. The system comprises a multi-source data acquisition module used for acquiring multi-source mammary gland related medical data of a target mammary nodule patient and preprocessing the multi-source mammary gland related medical data; the key prediction feature screening module is used for carrying out key feature screening on the preprocessed data to obtain mammary gland key prediction feature data; and the prediction module is used for inputting the breast key feature data into a pre-constructed breast nodule risk prediction model to obtain a corresponding breast nodule malignant transformation risk prediction result. According to the method, the related medical data of the multi-source mammary gland is integrated, and key feature screening and the mammary nodule risk prediction model are combined, so that the limitation of traditional single-dimensional evaluation is broken through, and early warning of malignant transformation of the mammary nodule is realized.

The invention discloses a marker combination for thyroid nodule risk assessment and application thereof. Based on large-sample multi-omics sequencing data, papillary thyroid carcinoma (PTC) and benign nodules are found to have a common epithelial spectrum origin, epithelial intermediate state cells (EICs) with malignant potential are found in the benign nodules, and typical molecular markers of the EICs are further identified to comprise ZCCHC12, CDLN1 and NPC2. The three genes participate in proliferation and differentiation of cells, the expression in PTC is remarkably up-regulated, and the malignant risk of the benign thyroid nodules can be evaluated by detecting the expression level of the markers in a biological sample. According to the method, a means for recognizing the high-risk benign nodules before malignant transformation occurs is provided for the first time, risk perspectiveness is achieved, and higher specificity and sensitivity are possibly achieved for recognizing the benign nodules with malignant potential.

The application provides a method for constructing an immortalized bovine nasopharyngeal tonsil epithelial cell line and application, and belongs to the technical field of cell engineering. The healthy yellow bovine nasopharyngeal tonsil is used as a material, and the primary epithelial cells are separated by enzyme digestion. The 3rd to 4th generation cells are taken, infected with SV40 T lentivirus (MOI=80), and screened by 1.5 μg / mL puromycin to obtain a stable immortalized cell line. The cell line is continuously passaged to the 50th generation and still stably expresses SV40LT protein and epithelial specific markers CD326, CD324 and KRT8, maintains a typical pavement stone-like morphology, normal proliferation and no malignant transformation. Infection experiments show that the cell is highly sensitive to FMDV, supports efficient replication, and the virus titer can reach 10 7.5 TCID 50 / mL. The application overcomes the defects of the existing immortalized bovine nasopharyngeal tonsil epithelial cell model, such as limited source, large batch difference, low sensitivity and poor persistence, and provides a stable and reliable in vitro model for the research of foot-and-mouth disease prevention and control related mechanisms, drug screening and vaccine development.

The invention provides a traditional Chinese medicine composition for improving acute and chronic abdominal inflammation and a preparation method thereof. The traditional Chinese medicine composition for improving acute and chronic abdominal inflammation can improve acute and chronic abdominal inflammation by optimizing the components of the formula and the content proportioning relationship among the components, has small side effects and quick response, and inhibits the process of transforming cells into malignant cells under the stimulation of chronic inflammation.

The invention discloses an application of circular RNA (Ribonucleic Acid) in tumor diagnosis and / or treatment. According to the present invention, high-throughput sequencing is adopted to detect the disordered expression circRNA in the metastasis cells, then a stable lung cancer cell model for overexpressing and knocking down the target circRNA is constructed, CCK-8 and transwell migration, invasion and other experiments are performed, and the cyclic structure of the circDCP2 and the up-regulation expression of the circDCP2 in the lung cancer cells are confirmed and verified, the result shows that knock-down of the circ DCP2 has a remarkable inhibition effect on the vicious transformation of BEAS-2B cells induced by the CBNPs. The circDCP2 can be used as a reliable biomarker for early lung cancer diagnosis and disease treatment.

This invention relates to a visual anti-reflux monitoring device for the digestive tract lumen, comprising a lumen section, an anti-reflux component, a cavity monitoring component, a guidewire, and a drive component. The top of the lumen section has a through-hole communicating with an internal cavity. The anti-reflux component is detachably connected to the outer side of the lumen section. The cavity monitoring component is installed outside the lumen section. The guidewire is installed within the through-hole of the lumen section and can rotate within the through-hole and move along the centerline of the through-hole. A first end of the guidewire is connected to the cavity monitoring component, and a second end of the guidewire is connected to the drive component, allowing adjustment of the monitoring angle and position of the cavity monitoring component. This invention achieves simultaneous monitoring and treatment of digestive tract diseases, reducing patient suffering and treatment costs, enabling early prevention of malignant transformation, simplifying medical procedures, and conserving medical resources—all public health benefits.

The invention particularly discloses siRNA for targeted knockdown of ITG beta1 and application of the siRNA, and relates to the field of molecular biology and biological medicine. The siRNA disclosed by the invention has the advantages that cell transfection is carried out by constructing a siRNA nucleotide sequence, and cell proliferation experiment results prove that the siRNA disclosed by the invention can obviously interfere with expression of ITGbeta1 and obviously inhibit proliferation and migration capabilities of human hepatoma carcinoma cell lines HepG2 and LM3, so that targeted therapy of metabolic dysfunction related fatty liver diseases is realized, and the siRNA has a good application prospect. Meanwhile, the malignant transformation from MASLD to HCC is effectively inhibited.

Embodiments described herein provide methods of determining a risk of progression of Barrett's esophagus in a subject, classifying Barrett's esophagus in a subject and detecting a field effect associated with malignant transformation of an esophagus of a subject suffering from Barrett's esophagus. The disclosure also provides kits for determining a risk of progression of Barrett's esophagus in a subject and classifying Barrett's esophagus in a subject.

The application discloses a method for improving the passaging times of a mammary epithelial cell line and application thereof, and belongs to the technical field of mammary epithelial cell lines. The application first finds that the exogenous fragment HS4-SAR fragment in the attachment area of the insulator-scaffold is connected with a p-Ef1a-SV40LT-Puro vector or a pEF1a-eGFP vector, and the transfection of commercial immortalized cell lines and primary cell lines can significantly improve the passaging times of the mammary epithelial cell lines, the cell morphology is still normal after 120 generations, the malignant transformation does not occur, the gene expression level does not decrease, and the immortalization is realized; the established goat mammary epithelial cell line still has the ability of synthesizing and secreting proteins; the method for improving the passaging times of the mammary epithelial cell line is simple and easy to operate, has a significant effect on the immortalized cell lines and the primary cell lines, and is expected to improve the stable passaging times of various mammary epithelial cell lines, and reduce the cell cost of related research.

This invention provides a method for constructing an esophageal cancer biomimetic organ model based on a complex hydrogel and its use, belonging to the field of medical biomimetic organ models. The biomimetic organ model is manufactured using a hydrogel as its framework. This invention constructs an in vitro biomimetic organ model of esophageal cancer with bioactivity, better simulates Pg infection in esophageal cancer patients, and finally introduces commonly used chemotherapy drugs to confirm the relationship between Pg and malignant changes in esophageal cancer, verify the drug screening function of the model, and compare it with clinical treatment effects.

The invention relates to the technical field of oral lesion risk screening, in particular to an oral mucosa malignant transformation risk model training method and system, a medium and equipment. The first oral cavity sample set comprises a plurality of groups of first spectrum selection images and second spectrum selection images shot for a plurality of first objects and second objects; the oral condition of the first object is healthy, and the oral condition of the second object is lesion or has a lesion trend; performing sample expansion on the first oral cavity sample set by adopting an image processing means to generate a second oral cavity sample set; and performing deep learning on the second oral cavity sample set by adopting a multi-order discarding mode so as to train and output an oral mucosa malignant transformation risk model. According to the oral mucosa malignant transformation risk model provided by the invention, the problems of gradient disappearance, overfitting and the like can be effectively avoided under a small oral cavity sample set, and the recognition accuracy is improved.

The invention discloses a construction method of an adult laryngeal papilloma organ. The construction method comprises the following steps: (1) receiving a sample and carrying out single-cell enzymolysis treatment; (2) 3D culture of adult laryngeal papilloma organs; and (3) passage and cryopreservation of adult laryngeal papilloma organs. The adult laryngeal papilloma organ-like model constructed by the method has histological characteristics similar to primary tissues, the culture method is simple and easy to implement, long-term in-vitro culture amplification can be realized, and the adult laryngeal papilloma organ-like model has the advantages of high genetic stability and the like. By using the method to construct a large number of adult laryngeal papilloma organ models, the occurrence and malignant transformation development of adult laryngeal papilloma can be better researched, and a personalized treatment scheme can be more effectively formulated for a patient.

The traditional Chinese medicine is prepared from 15-20 parts of platycodon grandiflorum, 15-20 parts of selfheal, 10-15 parts of pericarpium citri reticulatae, 10-20 parts of sculellaria barbata, 10-20 parts of oldenlandia diffusa, 12-15 parts of bamboo shavings and 10-15 parts of exocarpium citri grandis. The composition has huge advantages when being used for treating the pure ground glass pulmonary nodules, fills up the window period of regular follow-up visit of medium and low-risk pulmonary nodules without drug treatment, and has the advantages of early intervention, slowing down the progress of nodule malignant transformation, avoiding side effects and medical expenses caused by operations and the like.

The invention belongs to the technical field of biology, and discloses a marker for liver cancer diagnosis and a detection system and application of the marker, the marker is UDG and / or APE1, and an ECEER system for detecting the marker is a regular sequence system composed of a substrate chain Qc, a fuel chain Fu with a dU site and a fuel chain Fc and is used for detecting a target chain miR-(z); according to different target chains miR-(z), matched substrate chains Qc, fuel chains Fu and fuel chains Fc are designed, specific malignant transformed cells can be specifically recognized and analyzed, and high-sensitivity analysis of UDG and APE1 for different malignant transformed cells can be realized by simply changing an EDR reaction chain sequence. According to the method, the distinguishing precision of hierarchical decoding is ensured by adjusting the positions and the number of dU bases of a fuel chain and the number of mismatched bases; and the ECEER system is simple and convenient in preparation process, provides a new model for researching the relationship between UDG and APE1 and the process of malignant transformed cells, has clinical application potential, and can guide the diagnosis and treatment of the malignant transformed cells.

The invention discloses a gastric cancer biomarker ENO3 and a detection reagent thereof, belongs to the technical field of biological medicines, and particularly relates to a detection reagent of a gastric cancer marker. The detection reagent comprises an upstream primer and a downstream primer of a gastric cancer marker, and modified immunomagnetic beads, the gastric cancer marker is enolase 3. The invention finds and verifies that the gastric cancer marker enolase 3 promotes malignant transformation of gastric cancer by promoting glycolysis of gastric cancer cells, activating a WNT / beta-catenin signal channel and up-regulating expression of matrix metalloproteinase at the same time; meanwhile, by optimizing an immunomagnetic bead structure targeting the marker, the capture efficiency of the marker on trace tumor cells in peripheral blood is improved, so that the signal intensity of subsequent marker detection is enhanced, and an important tool is provided for improving the positive detection rate of gastric cancer detection based on the peripheral blood.

The invention relates to the technical field of biological medicine, in particular to application of SPP1 in treatment of pulmonary arterial hypertension, and is technically characterized in that SPP1 serves as multifunctional extracellular matrix protein to prepare medicine for treating pulmonary arterial hypertension, and the medicine is an inhibitor; the expression profile of the SPP1 is highly overlapped with the malignant transformation of the PAH. The invention also provides application of the SPP1 inhibitor in preparation of drugs for treating pulmonary arterial hypertension. The SPP1 serving as a multifunctional extracellular matrix protein in the scheme not only participates in pathological processes such as cell adhesion, signal transduction and inflammatory response, but also is proved to play an important role in tumor evolution, bone growth, immunoregulation and the like; the invention discloses a pulmonary arterial hypertension malignant transformation mechanism, abnormal proliferation of the pulmonary arterial hypertension can be inhibited in a targeted manner, pulmonary vascular remodeling is blocked, and a key treatment strategy is provided for treatment of pulmonary arterial hypertension.

The present application relates to a kind of eccDNA related to malignant transformation of hepatocellular carcinoma and its acquisition method and application, the nucleotide sequence of eccDNA is as shown in SEQ ID NO:1;The acquisition method and application of the eccDNA are also disclosed.The eccDNA obtained by the present application can exist stably in plasma and other body fluids, can be used for non-invasive or minimally invasive detection, can be used as early molecular marker of malignant transformation of hepatocellular carcinoma, and provides a new early warning idea of malignant transformation of hepatocellular carcinoma for the development of HBV-related liver cancer.

The invention belongs to the technical field of biology, and particularly relates to a PDCD10 protein molecule serving as a new target for early warning the final effect direction of arsenide-caused lung cancer and preventing the arsenide-caused lung cancer and application of the PDCD10 protein molecule. The invention discloses an application of a PDCD10 protein expression inhibitor in preparation of a medicine for preventing lung cancer caused by arsenide. After the PDCD10 is knocked down, the malignant effect of normal lung cells induced by the arsenide can be remarkably inhibited.

The invention discloses a series of engineered magnetic nano materials for metabolic crown characterization, a preparation method of the engineered magnetic nano materials, an integrated method of metabolic crown construction and corresponding metabonomics characterization based on the engineered magnetic nano materials, and application of the engineered magnetic nano materials in disease screening and diagnosis. The series of engineered magnetic nano-materials have differentiated surface function modifications, and when the engineered magnetic nano-materials are exposed to biological fluid, a unique metabolic crown can be formed. Through the disclosed integrated method for constructing and characterizing the biological fluid metabolic crown based on the series of engineered magnetic nano-materials, in-situ characterization of the metabolic crown on the surface of the nano-material can be directly realized through laser desorption ionization mass spectrometry detection without additional separation steps; obtained biological fluid metabolic crown mass spectrum data can be successfully applied to accurate discrimination and metabolic marker screening of endometriosis-related ovarian cancer patients, which shows that the biological fluid metabolic crown mass spectrum has a wide application prospect in the aspect of early screening of malignant transformation of endometriosis.

The invention discloses a construction method and application of an asbestos-caused lung carcinoma-in-situ animal model, and belongs to the technical field of biomedicine. The construction method comprises the following steps: firstly, carrying out multiple poisoning treatments on embryo fibroblasts by chrysotile, and then carrying out malignant transformation to obtain malignant transformed cells; a luciferase gene is introduced by utilizing lentivirus transfection; and injecting the successfully transfected malignant transformed cells into the lung of an experimental animal by adopting an intrapulmonary injection method, and feeding to obtain the lung carcinoma-in-situ animal model. The method creatively uses asbestos to induce malignant transformed embryo fibroblasts with cancerous characteristics to establish the lung in-situ cancer animal model, and has the advantages of short modeling period, high tumor formation rate, visualized cell transfer condition, capability of better reflecting the cancerous characteristics of asbestos and the like. The constructed model can be applied to clinical diagnosis and treatment research such as pathogenesis research and drug screening evaluation.

The present invention provides complexes for various therapeutic applications, as well as methods of treatment using the complexes or pharmaceutical compositions comprising the complexes. The complexes are particularly suitable for the treatment of malignant transformations, in particular cancer, in particular for the discovery of such transformations at sites remote from the site of administration of the complex, and for the treatment of metabolism-related diseases. The present invention relates to a complex comprising a polypeptide having a natural alpha-whey protein sequence, or a functional variant thereof, or a peptide comprising up to 50 amino acids of the alpha-helical domain of the polypeptide; and a fatty acid or lipid or a salt thereof.

The invention relates to a metabolic biomarker for malignant transformation of chronic hepatitis B and application of the metabolic biomarker, and belongs to the technical field of biomedicine. The invention provides aldehyde oxidase 1 (AOX1) and its downstream metabolite pyridoxal phosphate (PLP) as metabolic biomarkers for chronic hepatitis B malignant transformation. Through metabonomics and transcriptomics analysis, a'first-rising and second-falling 'dynamic trajectory of PLP rising in a chronic hepatitis B stage and falling in a liver cancer stage is found, and HBx reduces the PLP level by inhibiting AOX1 expression. The marker can be used for preparing a detection reagent, a kit or an integrated device, and dynamic monitoring and early warning of the vicious transformation risk are realized by detecting the AOX1 / PLP level in samples such as serum. The marker has the advantages of being clear in mechanism, high in dynamic relevance, suitable for clinical transformation and the like, and a new means is provided for liver cancer risk monitoring of chronic hepatitis B patients.

The invention relates to an application of a circ0002828 detection agent in preparation of a cervical cancer or cervical cancer prognosis reagent or kit. The circ0002828 has a nucleotide sequence as shown in SEQ ID NO. 1. The invention also provides an application of the circ0002828 in preparation of drugs for treating cervical cancer or metastasis of cervical cancer. The circ0002828 has a nucleotide sequence shown as SEQ ID NO.1. The invention discloses the tumor inhibition effect of the circ0002828 in cervical cancer for the first time. The circ0002828 has the functions of inhibiting proliferation, metastasis and angiogenesis of cervical cancer in vivo and in vitro. In mechanism, circ0002828 and DLGAP5 mRNA can be competitively combined with EIF4A3, so that the expression of DLGAP5 is reduced, the expression of gankyrin is increased, a p53 signal channel is activated, and tumor generation is inhibited. The circ0002828 is expected to become a candidate molecule for developing a novel cervical cancer treatment strategy.

The invention discloses a convenient-to-use hysteromyoma taking-out device for female reproductive system surgery, and relates to the technical field of medical instruments, in particular to a method for pushing away a bag through a displacement mechanism, expanding an opening of the bag after an annular bag is inflated through an inflation and deflation mechanism, and sleeving and wrapping myoma in an abdominal cavity through the opening of the bag. The myoma and the smashing assembly are wrapped together by the bag through the displacement mechanism, then gas in the annular bag is pumped out through the inflation and deflation mechanism, so that the opening of the bag is contracted, the annular bag drives the closing opening of the bag to be placed in the storage ring, and a closed smashing space is formed. Compared with an existing smashing protective sleeve which is prone to slipping, the bag is driven by the positioning rod to complete the myoma sleeving action, sealing after sleeving is completed by controlling the annular bag, slipping in an operation is avoided, it is guaranteed that the myoma smashing process is conducted in the bag, and the hidden danger that tissue debris generated by smashing is scattered to the abdominal cavity is avoided; the requirements of hysteromyoma diagnosis and treatment guidelines on malignant transformation risk prevention and control are met.

The application relates to application of a glutamine metabolism inhibitor V-9302 in preparation of a drug for treating diseases caused by cell malignant transformation of arsenic. The application is characterized in that the glutamine metabolism inhibitor V-9302 is used to inhibit the cell malignant transformation caused by arsenic, the malignant transformation phenotype of cells is reversed after the glutamine metabolism is inhibited, the cell doubling time is increased, the migration rate and the soft agar colony formation rate are reduced, and it is proved that the enhancement of the glutamine metabolism promotes the cell malignant transformation mediated by the synthesis of glutathione.

The invention provides an MDS malignant transformation risk assessment method based on machine learning and bone marrow cell morphology, and the method comprises the steps: S101, building a myelodysplastic syndrome (MDS) malignant transformation risk assessment model based on bone marrow morphology cell characteristics; s102, acquiring a bone marrow smear image of the MDS patient, identifying the bone marrow smear image, obtaining proportion data of the target type of bone marrow cells, and recording the proportion data as bone marrow cell type proportion data; s103, inputting the bone marrow cell type proportion data into an MDS malignant transformation risk assessment model, and calculating and outputting a risk assessment score of transformation from MDS to acute myelogenous leukemia (AML) of the patient; and S104, the patients are grouped according to the risk assessment scores, and a treatment scheme is recommended. The method has the advantages that the basic level is easy to obtain, the needed economic cost is low, calculation is convenient and the like, medical personnel can be assisted in optimizing treatment decisions, and the survival rate of high-risk patients is improved.

The application provides application of UBR5 in preparation of a drug for treating pigmented skin diseases, and further the pigmented skin diseases include various types of pigmented nevus (mainly congenital pigmented nevus and giant nevus with the risk of malignant transformation), various pigmented spots (mainly chloasma, freckle, nevus spilus, post-inflammatory pigmentation and the like) and hypopigmentation / loss of pigmentation spots (mainly vitiligo, post-inflammatory hypopigmentation and the like). The experimental results of the application show that UBR5 is highly expressed in the tissues of diseases such as pigmented nevus. The expression level of UBR5 is significantly positively correlated with the melanogenesis capacity, the expression level of proteins such as MITF, TRP1, TRP2 and TYR related to melanogenesis is significantly inhibited by targeted knockout / knockdown of UBR5 in melanocytes, the melanin content and tyrosinase activity of the melanocytes, and vice versa, the melanogenesis capacity of the melanocytes is significantly increased after overexpression of UBR5.

The invention provides miRNA for preventing and / or treating tumors and application of the miRNA, and belongs to the technical field of biological medicines. The invention discloses a brand new miRNA (micro Ribonucleic Acid) molecule novel-miR-75-5p, wherein the nucleotide sequence of the miRNA is as shown in SEQ ID NO. 1; the research of the invention finds that the miRNA molecule novel-miR-75-5p can be used for inhibiting the proliferation, migration, invasion and cloning capabilities of a malignant transformed cell (TGES-1); the miRNA molecule novel-miR-75-5p overexpression engineered OELNs can better inhibit malignant transformation (GES-1) of human normal gastric mucosa epithelial cells induced by MNNG, can be used for preparing drugs for preventing and / or treating gastric cancer, and has good practicability.